Both BioPharma Dive and STAT report that Roivant's immune drug brepocitinib met its goals in two Phase 3 trials in non-infectious uveitis, an inflammatory eye condition that can lead to blindness. The more detailed account from BioPharma Dive notes that patients treated with the drug went a median of more than 48 weeks before treatment failure, compared with 12 weeks for placebo, and also required no immunosuppressive steroids for 40 weeks.
Brepocitinib, now sold as Lisraya for the skin disease dermatomyositis, is developed by Priovant Therapeutics, a Roivant subsidiary. Priovant plans to submit a supplemental FDA application in the first half of next year. The trials also hit every secondary endpoint, including resolution of macular edema. BioPharma Dive quotes executives and analysts describing the drug as potentially "best-in-disease" and estimates a peak sales opportunity of $5 billion for uveitis.
The sources agree on the headline outcome; STAT's piece is a brief announcement without additional clinical detail. Neither source provides head-to-head comparison data, though BioPharma Dive notes that cross-trial comparisons suggest brepocitinib may outperform AbbVie's Humira.